Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Other Non-Current Liabilities (2019 - 2026)

Alx Oncology Holdings' Other Non-Current Liabilities history spans 5 years, with the latest figure at $7.2 million for Q4 2023.

  • On a quarterly basis, Other Non-Current Liabilities rose 35.59% to $7.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $7.2 million, a 35.59% increase, with the full-year FY2023 number at $7.2 million, up 35.59% from a year prior.
  • Other Non-Current Liabilities hit $7.2 million in Q4 2023 for Alx Oncology Holdings, up from $6.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for ALXO hit a ceiling of $7.2 million in Q4 2023 and a floor of $5000.0 in Q4 2020.
  • Historically, Other Non-Current Liabilities has averaged $3.5 million across 5 years, with a median of $3.5 million in 2021.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 99.09% in 2020 and later surged 36680.0% in 2021.
  • Tracing ALXO's Other Non-Current Liabilities over 5 years: stood at $547000.0 in 2019, then crashed by 99.09% to $5000.0 in 2020, then surged by 36680.0% to $1.8 million in 2021, then skyrocketed by 188.8% to $5.3 million in 2022, then surged by 35.59% to $7.2 million in 2023.
  • Business Quant data shows Other Non-Current Liabilities for ALXO at $7.2 million in Q4 2023, $6.6 million in Q3 2023, and $6.2 million in Q2 2023.